Artera

Company profile

About Artera

Artera is a precision oncology company that leverages multimodal artificial intelligence to personalize cancer treatment decisions. The company's AI platform analyzes digital pathology images and clinical data to provide actionable insights for cancer management. Artera's flagship product, the ArteraAI Prostate Test, is FDA-cleared and recommended in NCCN Clinical Practice Guidelines, offering therapeutic insights for early-stage prostate cancer patients. The test predicts which NCCN Intermediate-risk patients will benefit from short-term androgen deprivation therapy with radiation, and provides risk stratification for post-prostatectomy patients. The platform has been validated in dozens of large, randomized phase III clinical trials and demonstrates consistent performance across diverse populations, including African American and non-African American men. Artera also offers the ArteraAI Breast Cancer Test, which provides 5- and 10-year distant metastasis risk estimates for early-stage breast cancer patients and predicts chemotherapy benefit for node-negative patients 50 years or older. The company's tests utilize existing H&E slides without requiring additional tissue consumption or special staining, delivering results within 1-2 days through their CLIA-certified laboratory. Artera's mission is to establish a more personalized approach to cancer treatment by combining cutting-edge AI technology with clinical expertise.

Company description · Artera official website